Drugs / Aftobetin-HCl
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02928211 | Jul 2016 → Dec 2018 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Cognoptix, Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aftobetin-HCl | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02928211 ↗ |
| Modality | Diagnostic / imaging agent | “The medical imaging agent (the ointment), Aftobetin-HCl is an amyloid binding ligand formulated into an ophthalmic ointment.” NCT02928211 ↗ |
| Route | Topical | “formulated into an ophthalmic ointment” NCT02928211 ↗ |